Skip to main content
TipRanks
Go Ultimate75% OFF

Inventiva (6IVA) Stock Price & Analysis

2 Followers

6IVA Stock Chart & Stats

€3.46-€0.06(-1.70%)
At close: 5:30 PM GMT+1
€3.2€3.3€3.4Oct 28Nov 9
Day’s Range
EUR 3.26 - EUR 3.46
52-Week Range
EUR 2.32 - EUR 6.20
Previous Close
EUR 3.52
Volume
N/A
Average Volume (3M)
128
Market Cap
EUR 810.56M
Enterprise Value
EUR 920.42M
Total Cash (Recent Filing)
EUR 166.06M
Total Debt (Recent Filing)
EUR 66.63M
Price to Earnings (P/E)
―
Beta
1.03
Next Earnings
Mar 31, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Large Late-stage Clinical Program

A large, fully recruited Phase III program provides a substantial clinical test of lanifibranor across relevant MASH stages. The trial’s scale and advanced development status support a potentially meaningful value inflection if efficacy and safety results validate the program.

Promising Phase II Efficacy

The Phase II-B histological results provide clinical support for lanifibranor’s mechanism and help differentiate the lead asset in a disease with substantial unmet need. Reproducibility in Phase III could underpin regulatory progress and future commercial adoption.

Financing Supports Key Milestones

Runway extending through the anticipated Phase III readout and potential NDA filing reduces immediate funding pressure during the most important development period. This gives management greater ability to execute milestones before needing additional capital, subject to financing assumptions.

Bears Say

Deep And Persistent Operating Losses

Severe losses relative to revenue show that Inventiva has not yet achieved operating leverage and remains dependent on external financing. Continued development spending without commercial product sales could keep profitability distant and increase dilution or funding pressure.

Persistent Cash Burn And Weak Cash Generation

Ongoing negative operating and free cash flow means the business consumes cash to fund research and clinical development rather than generating internal resources. Higher recent burn can shorten financial flexibility and make future milestones more dependent on financing access.

Safety And Approval Uncertainty

Tolerability effects could affect treatment persistence, physician acceptance, or the eventual benefit-risk assessment for lanifibranor. Because regulatory filings and any commercial launch remain conditional on Phase III and approval outcomes, the lead program still carries material execution risk.

Inventiva News

6IVA FAQ

What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was €2.32 and its highest was €6.20 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is €810.56M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 135 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Sep 28, 2026. The company reported -€0.179 earnings per share for the quarter, beating the consensus estimate of -€0.339 by €0.161.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.29.
How many shares outstanding does Inventiva have?
Inventiva has 239,148,180 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -€0.179 in its last earnings report, beating expectations of -€0.339. Following the earnings report the stock price went up 2.92%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in DE:6IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology